Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

616 - Adenovirus-based antibody screening method and EphA2-targeted therapy

Date

10 Oct 2016

Session

Poster display

Presenters

Toshihiro Tanaka

Citation

Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392

Authors

T. Tanaka1, H. Yamada2, R. Nogami3, S. Kodama4, K. Tamura3, Y. Takamatsu3

Author affiliations

  • 1 Division Of Oncology, Hematology And Infectious Diseases, Department Of Internal Medicine, Fukuoka University School of Medicine, 814-0180 - Fukuoka/JP
  • 2 Biochemistry, Fukuoka University School of Medicine, Fukuoka/JP
  • 3 Division Of Oncology, Hematology And Infectious Diseases, Department Of Internal Medicine, Fukuoka University School of Medicine, Fukuoka/JP
  • 4 Regenerative Medicine & Transplantation, Fukuoka University School of Medicine, Fukuoka/JP
More

Resources

Abstract 616

Background

Development of a system that allows selective drug delivery into a cancer cell is expected to enable targeted therapy. We constructed a genetically modified adenovirus vector incorporating an IgG Fc-binding motif from staphylococcal protein A, Z33 (Adv-FZ33). Adv-FZ33 allows an antibody to redirect the vector to a target molecule on the cell surface. We attempted to search for target antigen candidates and antibodies that allowed highly selective gene transduction into malignant tumors.

Methods

Hybridoma libraries producing monoclonal antibodies (mAb) were screened that increased transduction efficiency in cancer cell lines after cross-linking with Adv-FZ33. Target antigens of the mAbs were identified by immunoprecipitation and mass spectrometry. Of these mAbs, we noted a clone, F2-27, that recognized the receptor tyrosine kinase EphA2. Next, we generated an adenovirus vector, Ax3CMTK-FZ33 that expressed a herpes simplex virus thymidine kinase (HSV-TK). The therapeutic efficacy of F2-27-mediated HSV-TK gene transduction, followed by ganciclovir (GCV) administration, was studied in vitro. The inhibitory effect of F2-27 on cancer cell invasion was investigated by a three-dimensional spheroid formation assay.

Results

In vitro reporter gene expression after Adv-FZ33 infection via F2-27 was 146 and 236 times higher than with control mAb or vector alone in EphA2-expressing cancer cell lines. F2-27-mediated Ax3CMTK-FZ33 infection induced the HSV-TK gene in a F2-27-dependent manner, and had a highly effective cytotoxic effect, in a GCV-dependent manner, on EphA2-positive cancer cell lines; the IC50 of GCV in F2-27 treated PC-3 cells was 0.37 mg/mL and that in isotype control mAb-treated cells was 39.28 mg/mL under the condition of a 1,000 VP/cell infection, showing a significant 106- fold difference. Additionally, F2-27 independently inhibited migration of EphA2-positive breast cancer cell lines in three-dimensional culture.

Conclusions

Our modified adenovirus and hybridoma screening system is useful for the development of targeted cancer therapy, and F2-27 has the potential to be an antibody-based therapy for various EphA2-positive cancers.

Clinical trial identification

Legal entity responsible for the study

Fukuoka University

Funding

Grant-in-Aid for Scientific Research (grant no. 22501054) from the Ministry of Education, Culture, Sports, Science and Technology of Japan

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings